- Home
- SLDB vs CKPT Comparison
SLDB vs CKPT Comparison
Compare SLDB & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- CKPT
- Stock Information
- Founded
- SLDB 2013
- CKPT 2014
- Country
- SLDB United States
- CKPT United States
- Employees
- SLDB N/A
- CKPT N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- SLDB Health Care
- CKPT Health Care
- Exchange
- SLDB Nasdaq
- CKPT Nasdaq
- Market Cap
- SLDB 227.3M
- CKPT 214.4M
- IPO Year
- SLDB 2018
- CKPT 2017
- Fundamental
- Price
- SLDB $4.03
- CKPT $3.68
- Analyst Decision
- SLDB Strong Buy
- CKPT Strong Buy
- Analyst Count
- SLDB 11
- CKPT 3
- Target Price
- SLDB $17.91
- CKPT $10.33
- AVG Volume (30 Days)
- SLDB 279.8K
- CKPT 2.2M
- Earning Date
- SLDB 11-06-2024
- CKPT 11-12-2024
- Dividend Yield
- SLDB N/A
- CKPT N/A
- EPS Growth
- SLDB N/A
- CKPT N/A
- EPS
- SLDB N/A
- CKPT N/A
- Revenue
- SLDB N/A
- CKPT $47,000.00
- Revenue This Year
- SLDB N/A
- CKPT N/A
- Revenue Next Year
- SLDB N/A
- CKPT $151,162.55
- P/E Ratio
- SLDB N/A
- CKPT N/A
- Revenue Growth
- SLDB N/A
- CKPT N/A
- 52 Week Low
- SLDB $4.00
- CKPT $1.38
- 52 Week High
- SLDB $15.05
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- SLDB 29.01
- CKPT 58.00
- Support Level
- SLDB $4.82
- CKPT $2.98
- Resistance Level
- SLDB $5.40
- CKPT $4.15
- Average True Range (ATR)
- SLDB 0.34
- CKPT 0.36
- MACD
- SLDB -0.08
- CKPT -0.06
- Stochastic Oscillator
- SLDB 1.63
- CKPT 75.43
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.